Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 10, 2024 16:10 ET
|
Pharvaris N.V.
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of...
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
April 10, 2024 16:08 ET
|
Pharvaris N.V.
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
April 04, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
March 18, 2024 06:50 ET
|
Pharvaris N.V.
The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks ...
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
March 06, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
March 05, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
February 22, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
Pharvaris Announces Extraordinary Meeting of Shareholders
February 16, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
Pharvaris to Present at the WSAAI Annual Meeting 2024
January 26, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
January 22, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...